Yescarta - Beechwood Capital

Yescarta axicabtagene ciloleucel APPROVED

Drug Profile

ModalityCell therapy

RouteIV

Therapy AreaOncology

Launch2017-10-18

US LOE2029-10-18

Peak Sales Est$2500M

Formulations[{"id":"yescarta-iv","route":"IV","setting":"INPATIENT","frequency":"Single infusion","is_primary":t

Companies

GILD (ORIGINATOR)100%

Mechanism: CD19 CAR-T

Expert: Autologous anti-CD19 CAR T-cell therapy for B-cell malignancies.

Everyday: Patient's own immune cells engineered to attack cancer cells with CD19 marker.

Targets: ["CD19"]

Revenue History

Programs (2)

Indication	Stage	Key Study	Regional Status
r/r DLBCL	APPROVED	ZUMA-1/ZUMA-7	[{"stage":"APPROVED","region":"US","approval_date":"2017-10-18"}]
Relapsed/refractory follicular lymphoma	APPROVED	ZUMA-5	[{"stage":"APPROVED","region":"US","approval_date":"2021-03-05"}]

Upcoming Catalysts (1)

Yescarta - 1L High-Risk LBCL - RMAT Data 2026

Notes

CD19 CAR-T for DLBCL, FL. Approved in 2L LBCL (2022). Outpatient administration expanding.

Data from Supabase · Updated 2026-03-24